Comparison of quality of life in patients with chronic obstructive pulmonary disease vaccinated with 13-valent conjugate pneumococcal vaccine or 23-valent polysaccharide pneumococcal vaccine
https://doi.org/10.18093/0869-0189-2015-25-2-163-166
Abstract
The aim of this study was to evaluate an impact of 13-valent conjugate pneumococcal vaccine (PCV-13) and 23-valent polysaccharide pneumococcal vaccine (PPV-23) on quality of life of patients with chronic obstructive pulmonary disease. Methods. We estimated quality of life from baseline to 12 months after the vaccination using the COPD Assessment Test (CAT). Results. The study involved 58 patients with COPD vaccinated with PCV-13 (n = 33) or PPV-23 (n = 25). The CAT score reduced by 10.3 in patients vaccinated with PCV-13 and by 8.8 in patients vaccinated with PPV-23 (p < 0.05). Conclusion. Vaccination of COPD patients with PCV-13 or PPV-23 could significantly improve quality of life. The conjugate vaccine PCV-13 is more preferable. Further studies of microbiological, immunological and other effects of PCV-13 and PPV-23 in COPD patients are needed.
About the Authors
M. P. Kostinov
Federal institution «I.I.Mechnikov Scientific and Research Vaccine and Serum Institute», Russian Science Academy: 5A, Malyy Kazennyy per., Moscow, 105064, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Laboratory of Vaccine Prevention and Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Healthcare Ministry of Russia; tel. / fax: (495) 917-41-49;
A. V. Zhestkov
State Institution «Samara State Medical University», Healthcare Ministry of Russia: 89, Chapaevskaya str., Samara, 443099, Russia;
Russian Federation
Russian Federation
MD, Professor, Head of Department of General and Clinical Microbiology, Immunology and Allergology, State Institution “Samara State Medical University”, Healthcare Ministry of Russia; tel. / fax: (846) 260-33-61;
A. D. Protasov
State Institution «Samara State Medical University», Healthcare Ministry of Russia: 89, Chapaevskaya str., Samara, 443099, Russia;
Russian Federation
Russian Federation
PhD, Assistant at the Department of General and Clinical Microbiology, Immunology and Allergology, State Institution “Samara State Medical University”, Healthcare Ministry of Russia; tel. / fax: (846) 260-33-61;
T. A. Kostinova
Federal institution «I.I.Mechnikov Scientific and Research Vaccine and Serum Institute», Russian Science Academy: 5A, Malyy Kazennyy per., Moscow, 105064, Russia
Russian Federation
Russian Federation
an allergist and immunologist, Laboratory of Vaccine Prevention and Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy; tel.: (495) 917-41-49;
D. V. Pakhomov
Federal institution «I.I.Mechnikov Scientific and Research Vaccine and Serum Institute», Russian Science Academy: 5A, Malyy Kazennyy per., Moscow, 105064, Russia
Russian Federation
Russian Federation
PhD, Senior Researcher, Laboratory of Vaccine Prevention and Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy; tel.: (495) 917-41-49;
A. V. Chebykina
Kirov Regional State Healthcare Institution «Kirov city hospital N9»: 97, Derendyaeva str., Kirov, 610027, Russia
Russian Federation
Russian Federation
PhD, Chief Pneumologist, Kirov Regional State Healthcare Institution "Kirov city hospital N9"; tel.: (905) 870-37-25;
O. O. Magarshak
Federal institution «I.I.Mechnikov Scientific and Research Vaccine and Serum Institute», Russian Science Academy: 5A, Malyy Kazennyy per., Moscow, 105064, Russia
Russian Federation
Russian Federation
PhD, Senior Researcher, Laboratory of Vaccine Prevention and Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy; tel.: (495) 917-41-49;
References
1. World Health Organization. Chronic obstructive pulmonary disease. 2012. Available at: http://www.who.int/mediacentre/factsheets/fs315/en/index.html
2. Protasov A.D. Immune and clinical effects of combined vaccination against pneumococcus, type B Haemophilus and influenza infections: Diss. Moscow; 2012 (in Russian).
3. Protasov A.D., Zhestkov A.V., Lavrent'eva N.E. et al. Effects of combined vaccination against pneumococcus, type B Haemophilus and influenza infections in patients with chronic obstructive pulmonary disease. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2011; 4: 80–84 (in Russian).
4. Perova A.L., Ruleva A.A. Vaccination against pneumococcus infection. Lechenie i profilaktika. 2013; 4 (8): 43–53 (in Russian).
5. Senkevich N.Yu., Khanova F.M., Safrygin K.V. Four questions about quality of life. Atmosfera. Pul'monologiya i allergologiya. 2002; 4: 26–28 (in Russian).
6. Protasov A.D., Zhestkov A.V., Kostinov M.P. The first experience of vaccination with 13-valent conjugate vaccine against pneumococcus in patients with chronic bronchopulmonary disease: safety and efficacy. Rossiyskiy allergologicheskiy zhurnal. 2013; 4: 18–23 (in Russian).
7. Protasov A.D. A comparative assessment of efficacy of 13-valent conjugate vaccine and 23-valent polysaccharide vaccine against pneumococcus in patients with chronic obstructive pulmonary disease. Rossiyskiy allergologicheskiy zhurnal. 2014; 4: 12–17 (in Russian).
8. Belevskiy A.S.,ed. Global Strategy for Diagnosis, Management, and Prevention of chronic obstructive pulmonary disease. Updated 2011. Moscow: Rossiyskoe respiratornoe obshchestvo; 2012 (in Russian).
Review
For citations:
Kostinov M.P., Zhestkov A.V., Protasov A.D., Kostinova T.A., Pakhomov D.V., Chebykina A.V., Magarshak O.O. Comparison of quality of life in patients with chronic obstructive pulmonary disease vaccinated with 13-valent conjugate pneumococcal vaccine or 23-valent polysaccharide pneumococcal vaccine. PULMONOLOGIYA. 2015;25(2):163-166. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-2-163-166
Views:
881
Email this article 